{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T21:10:44Z","timestamp":1761340244627,"version":"3.37.3"},"reference-count":18,"publisher":"Endocrinology Research Centre","issue":"6","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"DOI":"10.14341\/probl13351","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T18:16:18Z","timestamp":1706638578000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":2,"title":["Overcoming therapy resistance in prolactinomas: from perspectives to real clinical practice"],"prefix":"10.14341","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-7223","authenticated-orcid":true,"given":"A. S.","family":"Shutova","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-466X","authenticated-orcid":true,"given":"E. A.","family":"Pigarova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5779-3310","authenticated-orcid":true,"given":"L. I.","family":"Lepeshkina","sequence":"additional","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia named after Patrice Lumumba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-1662","authenticated-orcid":true,"given":"V. A.","family":"Ioutsi","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9431-8316","authenticated-orcid":true,"given":"M. Yu.","family":"Drokov","sequence":"additional","affiliation":[{"name":"National medical Research Center for Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-1676","authenticated-orcid":true,"given":"S. Y.","family":"Vorotnikova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-1902","authenticated-orcid":true,"given":"L. I.","family":"Astafyeva","sequence":"additional","affiliation":[{"name":"Burdenko Neurosurgical Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-4619","authenticated-orcid":true,"given":"L. K.","family":"Dzeranova","sequence":"additional","affiliation":[{"name":"National medical Research Center for Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: https:\/\/doi.org\/10.1210\/jc.2010-1692","key":"ref1","DOI":"10.1210\/jc.2010-1692"},{"doi-asserted-by":"crossref","unstructured":"Colao A. The prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(5):575-596. doi: https:\/\/doi.org\/10.1016\/j.beem.2009.05.003","key":"ref2","DOI":"10.1016\/j.beem.2009.05.003"},{"doi-asserted-by":"crossref","unstructured":"Kalmykova ZA, Vorotnikova SY, Fedorova NS, et al. The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation. Obesity and metabolism. 2019;16(2):89-94. (In Russ.)] doi: https:\/\/doi.org\/10.14341\/omet10243","key":"ref3","DOI":"10.14341\/omet10243"},{"doi-asserted-by":"crossref","unstructured":"Colao A., Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2011;7(5):267-278. doi: https:\/\/doi.org\/10.1038\/nrendo.2011.37","key":"ref4","DOI":"10.1038\/nrendo.2011.37"},{"doi-asserted-by":"crossref","unstructured":"Su Y-X, Du G-L, Shen H-L, et al. Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women. J Int Med Res. 2019;47(7):3115-3126. doi: https:\/\/doi.org\/10.1177\/0300060519848916","key":"ref5","DOI":"10.1177\/0300060519848916"},{"doi-asserted-by":"crossref","unstructured":"Fedorova NS, Abrosimov AY, Dzeranova LK, et al. Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics. Arkh Patol. 2018;80(3):34-39. (In Russ.). doi: https:\/\/doi.org\/10.17116\/patol201880334-39","key":"ref6","DOI":"10.17116\/patol201880334-39"},{"doi-asserted-by":"crossref","unstructured":"Fedorova NS, Dzeranova LK, Pigarova EA, et al. Tamoxifen in patients with dopamine agonist-resistant prolactinomas. Problems of Endocrinology. 2017;63(5):291-298. (In Russ.). doi: https:\/\/doi.org\/10.14341\/probl2017635291-298","key":"ref7","DOI":"10.14341\/probl2017635291-298"},{"doi-asserted-by":"crossref","unstructured":"Szmygin H, Szyde\u0142ko J, Matyjaszek-Matuszek B. Dopamine agonist-resistant microprolactinoma \u2014 mechanisms, predictors and management: A case report and literature review. JCM. 2022;11(11):3070. doi: https:\/\/doi.org\/10.3390\/jcm11113070","key":"ref8","DOI":"10.3390\/jcm11113070"},{"doi-asserted-by":"crossref","unstructured":"Ciccarelli A., Daly A. F., Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3-6. doi: https:\/\/doi.org\/10.1007\/s11102-005-5079-0","key":"ref9","DOI":"10.1007\/s11102-005-5079-0"},{"doi-asserted-by":"crossref","unstructured":"Colao A., Lombardi G. Growth-hormone and prolactin excess. The Lancet. 1998;352(9138):1455-1461. doi: https:\/\/doi.org\/10.1016\/S0140-6736(98)03356-X","key":"ref10","DOI":"10.1016\/S0140-6736(98)03356-X"},{"doi-asserted-by":"crossref","unstructured":"Dedov II, Mel\u2019nichenko GA, Romancova TI, et al. Giperprolaktinemiya. Sovremennye podhody i starye problem. Bulletin of Reproductive Health. 2009;(2):2-8. (In Russ.).","key":"ref11","DOI":"10.14341\/brh200922-8"},{"doi-asserted-by":"crossref","unstructured":"Mel\u2019nichenko GA, Dzeranova LK, Barmina II, et al. Rezistentnost\u2019 k terapii agonistami dofamina u patsientov s giperprolaktinemiey. Bulletin of Reproductive Health. 2007;(1):33-41. (In Russ.) doi: https:\/\/doi.org\/10.14341\/brh2007133-41","key":"ref12","DOI":"10.14341\/brh2007133-41"},{"doi-asserted-by":"crossref","unstructured":"Christian ZK, Hatanpaa KJ, Auchus RJ, et al. Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review. Interdiscip Neurosurg. 2020;21(3):100777. doi: https:\/\/doi.org\/10.1016\/j.inat.2020.100777","key":"ref13","DOI":"10.1016\/j.inat.2020.100777"},{"doi-asserted-by":"crossref","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485-534. doi: https:\/\/doi.org\/10.1210\/er.2005-9998","key":"ref14","DOI":"10.1210\/er.2005-9998"},{"doi-asserted-by":"crossref","unstructured":"L\u00f3pez JM, Oestreicher E. Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists. Fertil Steril. 2005;84(3):756.e11-756.e14. doi: https:\/\/doi.org\/10.1016\/j.fertnstert.2005.05.006","key":"ref15","DOI":"10.1016\/j.fertnstert.2005.05.006"},{"doi-asserted-by":"crossref","unstructured":"Olafsdottir A, Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab. 2006;2(10):552-561. doi: https:\/\/doi.org\/10.1038\/ncpendmet0290","key":"ref16","DOI":"10.1038\/ncpendmet0290"},{"doi-asserted-by":"crossref","unstructured":"Bykanova NS., Pigarova EA., Dzeranova LK. Prospects for the use of selective estrogen receptor modulator tamoxifen. Obesity and metabolism. 2012;9(1):9-13. (In Russ.). doi: https:\/\/doi.org\/10.14341\/2071-8713-5049","key":"ref17","DOI":"10.14341\/2071-8713-5049"},{"doi-asserted-by":"crossref","unstructured":"Jones ME, van Leeuwen FE, Hoogendoorn WE, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. Breast Cancer Res. 2012;14(3):R91. doi: https:\/\/doi.org\/10.1186\/bcr3206","key":"ref18","DOI":"10.1186\/bcr3206"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13351\/10590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T18:17:28Z","timestamp":1706638648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13351","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}